Hepatitis C Patients with HIV Co-Infection Vulnerable to Serious Liver Disease Despite Antiretroviral Therapy

Published Online: Friday, May 23, 2014
Follow Pharmacy_Times:
A study finds that patients co-infected with hepatitis C and HIV who are receiving antiretroviral therapy are 80% more likely to have serious liver disease than those with hepatitis C alone.

Co-infection with HIV in addition to hepatitis C virus (HCV) carries a higher risk of serious liver disease in patients even when they are receiving antiretroviral therapy (ART) than that found in patients with HCV alone, according to a new study by researchers at the University of Pennsylvania.
 
The study, published in the March 18, 2014, issue of Annals of Internal Medicine, compared outcomes in patients co-infected with HIV and HCV who were undergoing ART treatment with patients who have chronic HCV alone. HCV co-infection occurs in 10% to 30% of HIV-infected patients, according to the study authors.
 
To read the rest of this article on SpecialtyPharmacyTimes.com, click here.

Related Articles
The drugmaker will no longer pursue FDA approval of its dual daclatasvir and asunaprevir treatment for patients with hepatitis C virus genotype 1b.
Researchers from Saint Louis University Medical Center will test the safety and efficacy of sofosbuvir and ribavirin in children with hepatitis C.
Among HIV-positive patients, concurrent use of medications is associated with nonadherence to antiretroviral therapy.
Latest Issues
$auto_registration$